臺北榮民總醫院

:::

余文鍾 (Wen-Chung Yu)

掛號

Chien Y, Chou SJ, Chang YL, Leu HB, Yang YP, Tsai PH, Lai YH, Chen KH, Chang WC, Sung SH and Yu WC. Inhibition of Arachidonate 12/15-Lipoxygenase Improves alpha-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients. Int J Mol Sci. 2018;19(5):1480.
Huang WM, Lin YP, Chen CH and Yu WC. Tissue Doppler imaging predicts outcomes in hemodialysis patients with preserved left ventricular function. J Chin Med Assoc. 2019;82:351-355.
Wang WT, Sung SH, Liao JN, Hsu TR, Niu DM and Yu WC. Cardiac manifestations in patients with classical or cardiac subtype of Fabry disease. J Chin Med Assoc. 2020;83:825-829.
Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, Yang YJ, Niu DM and Yu WC. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:487-495.
Hung CL, Wu YW, Lin CC, Lai CH, Jyh-Ming Juang J, Chao TH, Kuo L, Sung KT, Wang CY, Wang CL, Chu CY, Yu WC and Hou CJ. 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease. Acta Cardiol Sin. 2021;37:337-354.

限於篇幅,以上謹為代表著作